News

Medicenna's Upcoming Presentation at the Global Investment Conference

Medicenna's Upcoming Presentation at the Global Investment Conference

Medicenna's Participation at H.C. Wainwright's Conference

Medicenna Therapeutics Corp. (NASDAQ: MDNA) is set to make a mark at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. The event takes place from September 8 to 10, bringing together thought leaders and innovators in the investment community.

Key Details About the Conference Presentation

Dr. Fahar Merchant, the President and CEO of Medicenna, will present to potential investors and engage in one-on-one meetings during the event. The conference will be held at the prestigious Lotte New York Palace Hotel, known for hosting significant financial discussions.

The specifics of Dr. Merchant's presentation are eagerly anticipated by stakeholders and enthusiasts in the biotechnology sector. It promises to showcase Medicenna's strategic plans and development efforts in cancer immunotherapy.

Presentation Schedule

The scheduled time for Dr. Merchant's presentation is on September 9, and it will occur from 2:30 PM to 3:00 PM Eastern Standard Time. Participants who wish to take part in the presentation can look forward to a thorough overview of the company’s innovations during this period.

Accessing the Live Webcast

For individuals who cannot attend in person, a webcast of the conference will be available. Viewers can find the webcast link on Medicenna’s official website. This initiative aligns with the company's commitment to transparency and accessibility for its investors and the public.

Impact of Medicenna's Innovations

Medicenna is paving the way for ground-breaking developments in the treatment of cancer through their focus on Superkines. Their lead product candidate, MDNA11, is designed to stimulate the immune system's T cells and NK cells effectively, offering an innovative approach to immune-oncology.

Furthermore, the company’s Empowered Superkine known as bizaxofusp has shown promise in multiple clinical trials. This approach specifically seeks to tackle recurring Glioblastoma Multiforme (GBM), a notoriously difficult form of brain cancer. With both FastTrack and Orphan Drug designations from the FDA, the treatment has gained attention for its potential to address this significant health challenge.

R&D Initiatives and Future Prospects

In addition to their lead candidates, Medicenna is exploring other options to strengthen its therapy portfolio. The introduction of their BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs speaks volumes about the company’s innovative spirit and commitment to advancing cancer treatment.

About Medicenna Therapeutics Corp.

Founded on the principles of innovation in cancer treatment, Medicenna has firmly established itself within the biotech industry. The company focuses on harnessing the potential of the immune system to combat cancer using differentiated therapies designed to maximize efficacy and minimize side effects.

Investor Relations Contact Information

Interested investors and media representatives can reach out to Shushu Feng, who handles investor relations for Medicenna. She can be contacted at (416) 964-5442 or via email. Stay updated on Medicenna’s advancements through their dedicated channels for investor relations.

Frequently Asked Questions

What is the H.C. Wainwright Global Investment Conference?

This conference is a significant event where companies engage with the investment community, presenting their projects and developments.

Where will the conference take place?

The event will be held at the Lotte New York Palace Hotel in New York City.

Who is presenting at the conference?

Dr. Fahar Merchant, the President and CEO of Medicenna, will make the presentation.

What is MDNA11?

MDNA11 is a next-generation IL-2 Superkine developed by Medicenna, aimed at improving cancer treatment outcomes.

How can I access Medicenna's presentation?

Those unable to attend can access a live webcast available on Medicenna’s website during the presentation.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 121

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 173

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 210

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 123

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 95

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 157

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 203

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading

Top 5 Most Recently Viewed Articles

dbt Labs Transforms Data Management with MetricFlow Open Source

Updated Category News Views 735

Embracing Open Source with MetricFlow In a groundbreaking move, dbt Labs recently announced its commitment to advancing trustworthy AI by open sourcing MetricFlow. This initiative represents a significant turning point in how organizations manage and utilize data in the era of artificial intelligence. The shift to an Apache 2.0 license not only safeguards the integrity of...

Continue Reading
EssilorLuxottica Achieves Euro 2 Billion Bond Issuance Success

Updated Category News Views 117

EssilorLuxottica's Successful Bond Issuance EssilorLuxottica has reached a noteworthy milestone by successfully issuing a Euro 2 billion bond at an attractive average rate of 2.99%. This strategic financial move highlights the company's strong position in the market and its appeal to investors. Details of the Bond Issuance The bond issuance features tenors of 4.5 years...

Continue Reading
Streamlined Home Selling Solutions Introduced in North Carolina

Updated Category News Views 292

Revolutionizing Home Selling in North Carolina Fair Cash Offers For Homes has recently launched its innovative service, ‘Sell Your House Fast North Carolina,’ designed to facilitate quick and efficient sales for homeowners. With the ever-changing real estate landscape, many individuals find themselves needing to sell their properties under various circumstances,...

Continue Reading
Ipsen Employee Admits to Insider Trading on Cancer Drug Deal

Updated Category News Views 268

Guilty Plea Tied to a Drugmaker’s Takeover Plans An employee at the French pharmaceutical company Ipsen has agreed to plead guilty to insider trading. The case, centered on trading ahead of a proposed acquisition, underscores the stakes around confidentiality in drug development and the pressures that test corporate governance. What Prosecutors Allege Dishant Gupta,...

Continue Reading
Oscar Health Achieves 52-Week Record with $23.45 Stock Price

Updated Category News Views 221

Oscar Health Achieves New Stock Performance Highs In a striking example of market resilience, Oscar Health, Inc. (OSCR) has reached an impressive 52-week high with its stock hitting $23.45. This achievement signifies a remarkable growth phase for the company, which has experienced an incredible one-year change of 288.51%. Investors have shown strong support for Oscar...

Continue Reading